Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | CTH | P32929 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | DDX3X | O00571 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434684 | 1.00 | MAPT (0.56) | MAPTRAB9AHTTNPC1CTH | |
| SCHEMBL21882639 | 0.91 | MAPT (0.49) | MAPTRAB9AHTTNPC1CTH | |
| SCHEMBL20834824 | 0.90 | ALDH1A1 (0.52) | MAPTRAB9AHTTNPC1CTH | |
| SCHEMBL17560759 | 0.83 | KMT2A (0.69) | MAPTRAB9AHTTNPC1GAA | |
| SCHEMBL17560913 | 0.83 | LMNA (0.66) | MAPTRAB9AHTTNPC1GAA | |
| SCHEMBL17560916 | 0.83 | LMNA (0.66) | MAPTRAB9AHTTNPC1GAA | |
| SCHEMBL17560761 | 0.83 | KMT2A (0.69) | MAPTRAB9AHTTNPC1GAA | |
| SCHEMBL17561004 | 0.83 | DDX3X (0.68) | MAPTRAB9AHTTNPC1CTH | |
| SCHEMBL17561007 | 0.83 | DDX3X (0.68) | MAPTRAB9AHTTNPC1CTH | |
| SCHEMBL16224338 | 0.82 | SMN1; SMN2 (0.57) | MAPTRAB9AHTTNPC1CTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | claimed |
| US-10370341-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-08-06 | — | — | US | claimed |
| US-10253002-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-04-09 | — | — | US | claimed |
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2019-03-21 | — | — | US | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | ELANE, IL1A, IL1B | MAPT 4207/4885RAB9A 3788/4885HTT 4128/4885 |
| US-10370341-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | MAPT 4207/4885RAB9A 3788/4885HTT 4128/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | MAPT 3694/4885RAB9A 3198/4885HTT 2244/4885 |
| US-10253002-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | MAPT 4207/4885RAB9A 3788/4885HTT 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.